Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.

Abstract

Randomized clinical trials suggest that the long-acting insulin analogs are associated with a lower risk for nocturnal hypoglycemia than neutral protamine Hagedorn without sacrificing glycemic control.